Advances in Diagnostic Approaches for Alzheimer's Disease: From Biomarkers to Deep Learning Technology.

Muhammad Asif, Hamid Ullah, Nelofer Jamil, Musarat Riaz, Maryam Zain, Peter Natesan Pushparaj, Mahmood Rasool
{"title":"Advances in Diagnostic Approaches for Alzheimer's Disease: From Biomarkers to Deep Learning Technology.","authors":"Muhammad Asif, Hamid Ullah, Nelofer Jamil, Musarat Riaz, Maryam Zain, Peter Natesan Pushparaj, Mahmood Rasool","doi":"10.2174/0118715273374284250519053646","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a devastating neurological disorder that affects humans and is a major contributor to dementia. It is characterized by cognitive dysfunction, impairing an individual's ability to perform daily tasks. In AD, nerve cells in areas of the brain related to cognitive function are damaged. Despite extensive research, there is currently no specific therapeutic or diagnostic approach for this fatal disease. However, scientists worldwide have developed effective techniques for diagnosing and managing this challenging disorder. Among the various methods used to diagnose AD are feedback from blood relatives and observations of changes in an individual's behavioral and cognitive abilities. Biomarkers, such as amyloid beta and measures of neurodegeneration, aid in the early detection of Alzheimer's disease (AD) through cerebrospinal fluid (CSF) samples and brain imaging techniques like Magnetic Resonance Imaging (MRI). Advanced medical imaging technologies, including X-ray, CT, MRI, ultrasound, mammography, and PET, provide valuable insights into human anatomy and function. MRI, in particular, is non-invasive and useful for scanning both the structural and functional aspects of the brain. Additionally, Machine Learning (ML) and deep learning (DL) technologies, especially Convolutional Neural Networks (CNNs), have demonstrated high accuracy in diagnosing AD by detecting brain changes. However, these technologies are intended to support, rather than replace, clinical assessments by medical professionals.</p>","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715273374284250519053646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer's disease (AD) is a devastating neurological disorder that affects humans and is a major contributor to dementia. It is characterized by cognitive dysfunction, impairing an individual's ability to perform daily tasks. In AD, nerve cells in areas of the brain related to cognitive function are damaged. Despite extensive research, there is currently no specific therapeutic or diagnostic approach for this fatal disease. However, scientists worldwide have developed effective techniques for diagnosing and managing this challenging disorder. Among the various methods used to diagnose AD are feedback from blood relatives and observations of changes in an individual's behavioral and cognitive abilities. Biomarkers, such as amyloid beta and measures of neurodegeneration, aid in the early detection of Alzheimer's disease (AD) through cerebrospinal fluid (CSF) samples and brain imaging techniques like Magnetic Resonance Imaging (MRI). Advanced medical imaging technologies, including X-ray, CT, MRI, ultrasound, mammography, and PET, provide valuable insights into human anatomy and function. MRI, in particular, is non-invasive and useful for scanning both the structural and functional aspects of the brain. Additionally, Machine Learning (ML) and deep learning (DL) technologies, especially Convolutional Neural Networks (CNNs), have demonstrated high accuracy in diagnosing AD by detecting brain changes. However, these technologies are intended to support, rather than replace, clinical assessments by medical professionals.

阿尔茨海默病诊断方法的进展:从生物标志物到深度学习技术。
阿尔茨海默病(AD)是一种影响人类的毁灭性神经系统疾病,是痴呆症的主要诱因。它的特点是认知功能障碍,损害个人执行日常任务的能力。在阿尔茨海默症中,大脑中与认知功能有关的区域的神经细胞受损。尽管进行了广泛的研究,但目前还没有针对这种致命疾病的特定治疗或诊断方法。然而,世界各地的科学家已经开发出有效的技术来诊断和治疗这种具有挑战性的疾病。在用于诊断AD的各种方法中,有来自血亲的反馈和对个体行为和认知能力变化的观察。生物标志物,如淀粉样蛋白和神经变性的测量,有助于通过脑脊液(CSF)样本和磁共振成像(MRI)等脑成像技术早期检测阿尔茨海默病(AD)。先进的医学成像技术,包括x射线、CT、MRI、超声波、乳房x光检查和PET,提供了对人体解剖和功能的宝贵见解。尤其是核磁共振成像,它是非侵入性的,对扫描大脑的结构和功能方面都很有用。此外,机器学习(ML)和深度学习(DL)技术,特别是卷积神经网络(cnn),已经证明了通过检测大脑变化来诊断AD的准确性。然而,这些技术旨在支持而不是取代医疗专业人员的临床评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信